ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

摘要:

Community hospitals and physicians are replicating the results obtained in clinical trials of thrombolytic therapy in patients with acute stroke. However, thrombolysis continues to reach far fewer stroke patients than the total number who might potentially benefit. Delays in initiating therapy and physician concerns about brain haemorrhage are major hindrances to increased use. New findings from the landmark US National Institute of Neurological Disorders and Stroke (NINDS) trial of alteplase [tPA, ‘Activase’] in patients with acute stroke show that treatment benefits are maintained for at least the first year after the intervention, delegates were told at the American Heart Association's 23rd Annual Joint Conference on Stroke and Cerebral Circulation [Orlando, US; February 1998].

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

摘要:

For 30 years, double-stranded RNA has been used in veterinary applications but has been considered too toxic for human use. However, recent molecular manipulation techniques have improved its tolerability, resulting in the agent ‘Ampligen’ [HemispheRx], which has been approved by the US FDA for clinical trials. The potential of ‘Ampligen’ for treating patients with chronic fatigue syndrome (CFS) was discussed at an international meeting entitled ‘The Clinical and Scientific Basis of Chronic Fatigue Syndrome: From Myth Towards Management’ [Sydney, Australia; February 1998].

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS